Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis

Summary

Podoplanin (PDPN) is expressed on many tumors and is involved in tumor metastasis. The objective of this study was to develop an ELISA for determining soluble PDPN (sPDPN) levels as a potential novel tumor marker in plasma of patients with cancers for detection of tumor occurrence and metastasis. Mouse monoclonal antibodies (mAbs) against human PDPN were developed and characterized. Two anti-PDPN mAbs, SZ-163 and SZ-168 were used in a sandwich ELISA to detect plasma sPDPN in patients with cancers and normal individuals. The levels of sPDPN were detected in patients with adenocarcinoma (87 cases, 31.09 ± 5.48 ng/mL), squamous cell carcinoma(86 cases, 6.91± 0.59ng/mL), lung cancer (45 cases, 26.10 ± 7.62 ng/mL), gastric cancer (38 cases, 23.71 ± 6.90 ng/mL), and rectal cancer (27 cases, 32.98 ± 9.88 ng/mL), which were significantly higher than those in normal individuals (99 cases, 1.31 ± 0.13 ng/mL) (P < 0.0001). Moreover, the sPDPN levels in patients with metastatic cancers were higher (192 cases, 30.35 ± 3.63 ng/mL) than those in non-metastatic cancer patients (92 cases, 6.28 ± 0.77 ng/mL) (P < 0.0001). The post-treatment sPDPN levels of cancer patients (n = 156) (4.47 ± 0.35 ng/mL) were significantly lower compared with those seen pre-treatment (n = 128) (43.74 ± 4.97 ng/mL) (P < 0.0001). These results showed that an ELISA method was successfully established for quantitation of plasma sPDPN and plasma sPDPN levels correlate significantly with tumor occurrence and metastasis.

This article is protected by copyright. All rights reserved.

http://ift.tt/2BuNR1w